GB9714249D0
(en)
|
1997-07-08 |
1997-09-10 |
Angiogene Pharm Ltd |
Vascular damaging agents
|
SE9903544D0
(sv)
|
1999-10-01 |
1999-10-01 |
Astra Pharma Prod |
Novel compounds
|
GB2359551A
(en)
|
2000-02-23 |
2001-08-29 |
Astrazeneca Uk Ltd |
Pharmaceutically active pyrimidine derivatives
|
AR028948A1
(es)
|
2000-06-20 |
2003-05-28 |
Astrazeneca Ab |
Compuestos novedosos
|
US6720323B2
(en)
|
2000-07-07 |
2004-04-13 |
Angiogene Pharmaceuticals Limited |
Colchinol derivatives as angiogenesis inhibitors
|
CN1255391C
(zh)
*
|
2000-07-07 |
2006-05-10 |
安吉奥金尼药品有限公司 |
作为血管破坏剂的colchinol衍生物
|
SE0003828D0
(sv)
|
2000-10-20 |
2000-10-20 |
Astrazeneca Ab |
Novel compounds
|
US6919324B2
(en)
|
2001-10-26 |
2005-07-19 |
Oxigene, Inc. |
Functionalized stilbene derivatives as improved vascular targeting agents
|
CN101607958A
(zh)
|
2002-02-01 |
2009-12-23 |
阿斯特拉曾尼卡有限公司 |
喹唑啉化合物
|
GB0217431D0
(en)
|
2002-07-27 |
2002-09-04 |
Astrazeneca Ab |
Novel compounds
|
DE60318219T2
(de)
|
2002-08-24 |
2009-01-15 |
Astrazeneca Ab |
PYRIMIDINDERIVATE ALS MODULATOREN DER AKTIVITuT VON CHEMOKINREZEPTOREN
|
GB0221828D0
(en)
|
2002-09-20 |
2002-10-30 |
Astrazeneca Ab |
Novel compound
|
DK1847539T3
(da)
|
2002-12-24 |
2009-11-09 |
Astrazeneca Ab |
Quinazolin-derivater
|
WO2004078126A2
(en)
|
2003-02-28 |
2004-09-16 |
Oxigene, Inc. |
Compositions and methods with enhanced therapeutic activity
|
SE0301010D0
(sv)
|
2003-04-07 |
2003-04-07 |
Astrazeneca Ab |
Novel compounds
|
SE0301569D0
(sv)
|
2003-05-27 |
2003-05-27 |
Astrazeneca Ab |
Novel compounds
|
WO2005051302A2
(en)
|
2003-11-19 |
2005-06-09 |
Array Biopharma Inc. |
Bicyclic inhibitors of mek and methods of use thereof
|
GB0328243D0
(en)
|
2003-12-05 |
2004-01-07 |
Astrazeneca Ab |
Methods
|
GB0329771D0
(en)
*
|
2003-12-23 |
2004-01-28 |
Angiogene Pharm Ltd |
Chemical processes & intermediates
|
EP1732920B1
(en)
|
2004-01-05 |
2011-03-09 |
AstraZeneca AB |
Thiophene derivatives as chk 1 inhibitors
|
SE0401657D0
(sv)
|
2004-06-24 |
2004-06-24 |
Astrazeneca Ab |
Chemical compounds
|
GB0415320D0
(en)
|
2004-07-08 |
2004-08-11 |
Astrazeneca Ab |
Novel compounds
|
EP1809624B1
(en)
|
2004-08-28 |
2013-11-20 |
AstraZeneca AB |
Pyrimidine sulphonamide derivatives as chemokine receptor modulators
|
RS52036B
(en)
|
2004-12-21 |
2012-04-30 |
Medimmune Limited |
ANGIOPOETIN-2 ANTIBODIES AND ITS USES
|
GB0428100D0
(en)
*
|
2004-12-23 |
2005-01-26 |
Astrazeneca Ab |
Chemical processes & intermediates
|
ES2375735T3
(es)
|
2005-02-04 |
2012-03-05 |
Astrazeneca Ab |
Derivados de pirazolilaminopiridina útiles como inhibidores de quinasas.
|
EP2402316A1
(en)
|
2005-07-21 |
2012-01-04 |
AstraZeneca AB (Publ) |
Piperidine derivatives
|
TW200738634A
(en)
|
2005-08-02 |
2007-10-16 |
Astrazeneca Ab |
New salt
|
TW200738658A
(en)
|
2005-08-09 |
2007-10-16 |
Astrazeneca Ab |
Novel compounds
|
JPWO2007034817A1
(ja)
|
2005-09-22 |
2009-03-26 |
大日本住友製薬株式会社 |
新規アデニン化合物
|
US20090192153A1
(en)
|
2005-09-22 |
2009-07-30 |
Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan |
Novel adenine compound
|
EP1939199A4
(en)
|
2005-09-22 |
2010-10-20 |
Dainippon Sumitomo Pharma Co |
NEW ADENINE CONNECTION
|
WO2007034916A1
(ja)
|
2005-09-22 |
2007-03-29 |
Dainippon Sumitomo Pharma Co., Ltd. |
新規アデニン化合物
|
EP1939201A4
(en)
|
2005-09-22 |
2010-06-16 |
Dainippon Sumitomo Pharma Co |
NEW ADENINE CONNECTION
|
US8148572B2
(en)
|
2005-10-06 |
2012-04-03 |
Astrazeneca Ab |
Compounds
|
EP2388259A1
(en)
|
2005-10-28 |
2011-11-23 |
AstraZeneca AB |
4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
|
ZA200804498B
(en)
|
2005-11-15 |
2009-07-29 |
Array Biopharma Inc |
N4-phenyl-quinazoline-4 -amine derivatives and related compounds as ERBB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
|
TW200730512A
(en)
|
2005-12-12 |
2007-08-16 |
Astrazeneca Ab |
Novel compounds
|
EP1979001B1
(en)
|
2005-12-13 |
2012-04-11 |
Medimmune Limited |
Binding proteins specific for insulin-like growth factors and uses thereof
|
ES2380683T3
(es)
|
2005-12-15 |
2012-05-17 |
Astrazeneca Ab |
Difenil-éteres, -amidas, -sulfuros y - metanos sustituidos para el tratamiento de la enfermedad respiratoria
|
TW200813091A
(en)
|
2006-04-10 |
2008-03-16 |
Amgen Fremont Inc |
Targeted binding agents directed to uPAR and uses thereof
|
EP2125722A2
(en)
|
2006-05-26 |
2009-12-02 |
AstraZeneca AB |
Bi-aryl or aryl-heteroaryl substituted indoles
|
CL2007002225A1
(es)
|
2006-08-03 |
2008-04-18 |
Astrazeneca Ab |
Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
|
DE102006037478A1
(de)
|
2006-08-10 |
2008-02-14 |
Merck Patent Gmbh |
2-(Heterocyclylbenzyl)-pyridazinonderivate
|
HUE033894T2
(en)
*
|
2006-08-23 |
2018-01-29 |
Kudos Pharm Ltd |
2-Methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as MTOR inhibitors
|
TW200825084A
(en)
|
2006-11-14 |
2008-06-16 |
Astrazeneca Ab |
New compounds 521
|
TW200831528A
(en)
|
2006-11-30 |
2008-08-01 |
Astrazeneca Ab |
Compounds
|
ES2385681T3
(es)
|
2006-12-19 |
2012-07-30 |
Astrazeneca Ab |
Derivados de quinuclidinol como antagonistas de receptores muscarínicos
|
CL2008000191A1
(es)
|
2007-01-25 |
2008-08-22 |
Astrazeneca Ab |
Compuestos derivados de 4-amino-cinnotina-3-carboxamida; inhibidores de csf-1r quinasa; su proceso de preparacion; y su uso para tratar el cancer.
|
AR065784A1
(es)
|
2007-03-20 |
2009-07-01 |
Dainippon Sumitomo Pharma Co |
Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas.
|
JPWO2008114819A1
(ja)
|
2007-03-20 |
2010-07-08 |
大日本住友製薬株式会社 |
新規アデニン化合物
|
UA99459C2
(en)
|
2007-05-04 |
2012-08-27 |
Астразенека Аб |
9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
|
DE102007025718A1
(de)
|
2007-06-01 |
2008-12-04 |
Merck Patent Gmbh |
Pyridazinonderivate
|
DE102007025717A1
(de)
|
2007-06-01 |
2008-12-11 |
Merck Patent Gmbh |
Arylether-pyridazinonderivate
|
DE102007026341A1
(de)
|
2007-06-06 |
2008-12-11 |
Merck Patent Gmbh |
Benzoxazolonderivate
|
UA100983C2
(ru)
|
2007-07-05 |
2013-02-25 |
Астразенека Аб |
Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты
|
DE102007032507A1
(de)
|
2007-07-12 |
2009-04-02 |
Merck Patent Gmbh |
Pyridazinonderivate
|
DE102007038957A1
(de)
|
2007-08-17 |
2009-02-19 |
Merck Patent Gmbh |
6-Thioxo-pyridazinderivate
|
DE102007041115A1
(de)
|
2007-08-30 |
2009-03-05 |
Merck Patent Gmbh |
Thiadiazinonderivate
|
MX2010003698A
(es)
|
2007-10-04 |
2010-04-21 |
Astrazeneca Ab |
Compuestos de [3,2-c]pirazol esteroides con actividad glucocorticoide.
|
RS53552B1
(en)
|
2007-10-11 |
2015-02-27 |
Astrazeneca Ab |
DERIVATI PIROLO [2,3-D] PIRIMIDINA KAO INHIBITORI PROTEIN KINAZE B
|
US8092804B2
(en)
|
2007-12-21 |
2012-01-10 |
Medimmune Limited |
Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
|
DE102007061963A1
(de)
|
2007-12-21 |
2009-06-25 |
Merck Patent Gmbh |
Pyridazinonderivate
|
EP2245064B1
(en)
|
2007-12-21 |
2014-07-23 |
Medimmune Limited |
BINDING MEMBERS FOR INTERLEUKIN-4 RECEPTOR ALPHA (IL-4Ralpha)
|
ES2394547T3
(es)
|
2008-02-06 |
2013-02-01 |
Astrazeneca Ab |
Compuestos
|
WO2009108670A1
(en)
|
2008-02-28 |
2009-09-03 |
Merck Serono S.A. |
Protein kinase inhibitors and use thereof
|
DE102008019907A1
(de)
|
2008-04-21 |
2009-10-22 |
Merck Patent Gmbh |
Pyridazinonderivate
|
BRPI0912103A2
(pt)
|
2008-05-27 |
2021-04-20 |
Astrazeneca Ab |
derivados de fenoxipiridinilamida e seu uso no tratamento de estados de doenças mediados por pde4
|
DE102008025750A1
(de)
|
2008-05-29 |
2009-12-03 |
Merck Patent Gmbh |
Dihydropyrazolderivate
|
DE102008028905A1
(de)
|
2008-06-18 |
2009-12-24 |
Merck Patent Gmbh |
3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
|
DE102008029734A1
(de)
|
2008-06-23 |
2009-12-24 |
Merck Patent Gmbh |
Thiazolyl-piperidinderivate
|
TWI461423B
(zh)
|
2008-07-02 |
2014-11-21 |
Astrazeneca Ab |
用於治療Pim激酶相關病狀及疾病之噻唑啶二酮化合物
|
DE102008037790A1
(de)
|
2008-08-14 |
2010-02-18 |
Merck Patent Gmbh |
Bicyclische Triazolderivate
|
DE102008038221A1
(de)
|
2008-08-18 |
2010-02-25 |
Merck Patent Gmbh |
7-Azaindolderivate
|
CA2735900A1
(en)
|
2008-09-19 |
2010-03-25 |
Medimmune, Llc |
Antibodies directed to dll4 and uses thereof
|
DE102008052943A1
(de)
|
2008-10-23 |
2010-04-29 |
Merck Patent Gmbh |
Azaindolderivate
|
WO2010067102A1
(en)
|
2008-12-09 |
2010-06-17 |
Astrazeneca Ab |
Diazaspiro [5.5] undecane derivatives and related compounds as muscarinic-receptor antagonists and beta-adrenoreceptor agonists for the treatment of pulmonary disorders
|
CN104860913B
(zh)
|
2008-12-11 |
2018-05-04 |
艾克赛特药品有限公司 |
染料木黄酮的晶型
|
US7863325B2
(en)
|
2008-12-11 |
2011-01-04 |
Axcentua Pharmaceuticals Ab |
Crystalline genistein sodium salt dihydrate
|
US20100152197A1
(en)
|
2008-12-15 |
2010-06-17 |
Astrazeneca Ab |
(4-tert-butylpiperazin-2-yl)(piperazin-1-yl)methanone-n-carboxamide derivatives
|
AU2009333653B2
(en)
|
2008-12-17 |
2015-09-10 |
Merck Patent Gmbh |
C-ring modified tricyclic benzonaphthiridinone protein kinase inhibitors and use thereof
|
DE102008063667A1
(de)
|
2008-12-18 |
2010-07-01 |
Merck Patent Gmbh |
3-(3-Pyrimidin-2-yl-benzyl)-°[1,2,4]triazolo[4,3-b]pyrimidin-derivate
|
CA2745085C
(en)
|
2008-12-18 |
2018-03-06 |
Merck Patent Gmbh |
Tricyclic azaindoles
|
TW201028410A
(en)
|
2008-12-22 |
2010-08-01 |
Astrazeneca Ab |
Chemical compounds 610
|
DE102008062826A1
(de)
|
2008-12-23 |
2010-07-01 |
Merck Patent Gmbh |
Pyridazinonderivate
|
US20120114667A1
(en)
|
2008-12-23 |
2012-05-10 |
Medimmune Limited |
TARGETED BINDING AGENTS DIRECTED TO a5BETA1 AND USES THEREOF
|
DE102008062825A1
(de)
|
2008-12-23 |
2010-06-24 |
Merck Patent Gmbh |
3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo [4,3-b]pyridazin-derivate
|
DE102009003954A1
(de)
|
2009-01-07 |
2010-07-08 |
Merck Patent Gmbh |
Pyridazinonderivate
|
DE102009003975A1
(de)
|
2009-01-07 |
2010-07-08 |
Merck Patent Gmbh |
Benzothiazolonderivate
|
DE102009004061A1
(de)
|
2009-01-08 |
2010-07-15 |
Merck Patent Gmbh |
Pyridazinonderivate
|
WO2010089580A1
(en)
|
2009-02-06 |
2010-08-12 |
Astrazeneca Ab |
Use of a mct1 inhibitor in the treatment of cancers expressing mct1 over mct4
|
AU2010212590B2
(en)
|
2009-02-10 |
2013-01-10 |
Astrazeneca Ab |
Triazolo [4,3-b] pyridazine derivatives and their uses for prostate cancer
|
GB0905127D0
(en)
|
2009-03-25 |
2009-05-06 |
Pharminox Ltd |
Novel prodrugs
|
UY32520A
(es)
|
2009-04-03 |
2010-10-29 |
Astrazeneca Ab |
Compuestos que tienen actividad agonista del receptor de glucocorticoesteroides
|
US8389580B2
(en)
|
2009-06-02 |
2013-03-05 |
Duke University |
Arylcyclopropylamines and methods of use
|
US20100317593A1
(en)
|
2009-06-12 |
2010-12-16 |
Astrazeneca Ab |
2,3-dihydro-1h-indene compounds
|
GB0913342D0
(en)
|
2009-07-31 |
2009-09-16 |
Astrazeneca Ab |
Compounds - 801
|
DE102009043260A1
(de)
|
2009-09-28 |
2011-04-28 |
Merck Patent Gmbh |
Pyridinyl-imidazolonderivate
|
MX2012003644A
(es)
|
2009-10-02 |
2012-04-30 |
Astrazeneca Ab |
Compuestos de 2-piridona empleados como inhibidores de la elastasa neutrofila.
|
DE102009049679A1
(de)
|
2009-10-19 |
2011-04-21 |
Merck Patent Gmbh |
Pyrazolopyrimidinderivate
|
WO2011048409A1
(en)
|
2009-10-20 |
2011-04-28 |
Astrazeneca Ab |
Cyclic amine derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
|
US8399460B2
(en)
|
2009-10-27 |
2013-03-19 |
Astrazeneca Ab |
Chromenone derivatives
|
MX2012005329A
(es)
|
2009-11-18 |
2012-05-29 |
Astrazeneca Ab |
Compuestos benzoimidazolicos y sus usos.
|
DK3279215T3
(da)
|
2009-11-24 |
2020-04-27 |
Medimmune Ltd |
Målrettede bindemidler mod b7-h1
|
EP2507237A1
(en)
|
2009-12-03 |
2012-10-10 |
Dainippon Sumitomo Pharma Co., Ltd. |
Imidazoquinolines which act via toll - like receptors (tlr)
|
EP2513057B1
(de)
|
2009-12-14 |
2013-09-04 |
Merck Patent GmbH |
Inhibitoren der sphingosinkinase
|
DE102009058280A1
(de)
|
2009-12-14 |
2011-06-16 |
Merck Patent Gmbh |
Thiazolderivate
|
JP2013514287A
(ja)
|
2009-12-17 |
2013-04-25 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
スフィンゴシンキナーゼの阻害薬
|
ES2654584T3
(es)
|
2010-01-15 |
2018-02-14 |
Suzhou Neupharma Co., Ltd |
Ciertas entidades químicas, composiciones y métodos
|
AU2011208530A1
(en)
|
2010-01-19 |
2012-08-09 |
Astrazeneca Ab |
Pyrazine derivatives
|
WO2011095807A1
(en)
|
2010-02-07 |
2011-08-11 |
Astrazeneca Ab |
Combinations of mek and hh inhibitors
|
WO2011114148A1
(en)
|
2010-03-17 |
2011-09-22 |
Astrazeneca Ab |
4h- [1, 2, 4] triazolo [5, 1 -b] pyrimidin-7 -one derivatives as ccr2b receptor antagonists
|
US20130059916A1
(en)
|
2010-05-26 |
2013-03-07 |
Stephane Rocchi |
Biguanide compounds and its use for treating cancer
|
WO2011154677A1
(en)
|
2010-06-09 |
2011-12-15 |
Astrazeneca Ab |
Substituted n-[1-cyano-2-(phenyl)ethyl] 1-aminocycloalk-1-ylcarboxamide compounds - 760
|
GB201009801D0
(en)
|
2010-06-11 |
2010-07-21 |
Astrazeneca Ab |
Compounds 950
|
SA111320519B1
(ar)
|
2010-06-11 |
2014-07-02 |
Astrazeneca Ab |
مركبات بيريميدينيل للاستخدام كمثبطات atr
|
TW201219383A
(en)
|
2010-08-02 |
2012-05-16 |
Astrazeneca Ab |
Chemical compounds
|
TWI535712B
(zh)
|
2010-08-06 |
2016-06-01 |
阿斯特捷利康公司 |
化合物
|
DE102010034699A1
(de)
|
2010-08-18 |
2012-02-23 |
Merck Patent Gmbh |
Pyrimidinderivate
|
WO2012027957A1
(en)
|
2010-08-28 |
2012-03-08 |
Suzhou Neupharma Co., Ltd. |
Bufalin derivatives, pharmaceutical compositions and use thereof
|
GB201016442D0
(en)
|
2010-09-30 |
2010-11-17 |
Pharminox Ltd |
Novel acridine derivatives
|
DE102010048800A1
(de)
|
2010-10-20 |
2012-05-10 |
Merck Patent Gmbh |
Chinoxalinderivate
|
DE102010049595A1
(de)
|
2010-10-26 |
2012-04-26 |
Merck Patent Gmbh |
Chinazolinderivate
|
WO2012066336A1
(en)
|
2010-11-19 |
2012-05-24 |
Astrazeneca Ab |
Benzylamine compounds as toll -like receptor 7 agonists
|
WO2012067268A1
(en)
|
2010-11-19 |
2012-05-24 |
Dainippon Sumitomo Pharma Co., Ltd. |
Cyclic amide compounds and their use in the treatment of disease
|
WO2012067269A1
(en)
|
2010-11-19 |
2012-05-24 |
Dainippon Sumitomo Pharma Co., Ltd. |
Aminoalkoxyphenyl compounds and their use in the treatment of disease
|
WO2012066335A1
(en)
|
2010-11-19 |
2012-05-24 |
Astrazeneca Ab |
Phenol compounds als toll -like receptor 7 agonists
|
ES2575688T3
(es)
|
2010-12-16 |
2016-06-30 |
Sumitomo Dainippon Pharma Co., Ltd. |
Derivado de imidazo[4,5-c]quinolin-1-ilo útil en terapia
|
EP2651943B1
(en)
|
2010-12-17 |
2017-03-22 |
Sumitomo Dainippon Pharma Co., Ltd. |
Purine derivatives
|
CA2822515C
(en)
|
2010-12-20 |
2023-04-25 |
Medimmune Limited |
Anti-il-18 antibodies and their uses
|
EP2670763B1
(en)
|
2011-02-02 |
2018-08-01 |
Suzhou Neupharma Co., Ltd |
Certain chemical entities, compositions, and methods
|
CA2827172C
(en)
|
2011-02-17 |
2019-02-26 |
Cancer Therapeutics Crc Pty Limited |
Selective fak inhibitors
|
US20130324532A1
(en)
|
2011-02-17 |
2013-12-05 |
Cancer Therapeutics Crc Pty Limited |
Fak inhibitors
|
GB201104267D0
(en)
|
2011-03-14 |
2011-04-27 |
Cancer Rec Tech Ltd |
Pyrrolopyridineamino derivatives
|
US8530470B2
(en)
|
2011-04-13 |
2013-09-10 |
Astrazeneca Ab |
Chromenone derivatives
|
WO2012175991A1
(en)
|
2011-06-24 |
2012-12-27 |
Pharminox Limited |
Fused pentacyclic anti - proliferative compounds
|
US20140227293A1
(en)
|
2011-06-30 |
2014-08-14 |
Trustees Of Boston University |
Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
|
MY180039A
(en)
|
2011-07-12 |
2020-11-20 |
Astrazeneca Ab |
N- (6- ( (2r,3s) -3,4-dihydroxybutan-2-yloxy) -2- (4 - fluorobenzylthio) pyrimidin- 4 - yl) -3- methylazetidine- 1 - sulfonamide as chemokine receptor modulator
|
RS60190B1
(sr)
|
2011-07-27 |
2020-06-30 |
Astrazeneca Ab |
2-(2,4,5-supstituisani-anilino) pirimidinski derivati kao egfr modulatori korisni za lečenje raka
|
ES2587847T3
(es)
|
2011-07-29 |
2016-10-27 |
Medicinova, Inc. |
Di-hidrocloruro de denibulina
|
DE102011111400A1
(de)
|
2011-08-23 |
2013-02-28 |
Merck Patent Gmbh |
Bicyclische heteroaromatische Verbindungen
|
WO2013032951A1
(en)
|
2011-08-26 |
2013-03-07 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
US9328081B2
(en)
|
2011-09-01 |
2016-05-03 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
WO2013040515A1
(en)
|
2011-09-14 |
2013-03-21 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
US9249110B2
(en)
|
2011-09-21 |
2016-02-02 |
Neupharma, Inc. |
Substituted quinoxalines as B-raf kinase inhibitors
|
WO2013045955A1
(en)
|
2011-09-29 |
2013-04-04 |
The University Of Liverpool |
Prevention and/or treatment of cancer and/or cancer metastasis
|
US9249111B2
(en)
|
2011-09-30 |
2016-02-02 |
Neupharma, Inc. |
Substituted quinoxalines as B-RAF kinase inhibitors
|
US20130178520A1
(en)
|
2011-12-23 |
2013-07-11 |
Duke University |
Methods of treatment using arylcyclopropylamine compounds
|
WO2013112950A2
(en)
|
2012-01-25 |
2013-08-01 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
AU2012367141B2
(en)
|
2012-01-28 |
2016-12-22 |
Merck Patent Gmbh |
Triazolo[4,5-d]pyrimidine derivatives
|
WO2013117285A1
(en)
|
2012-02-09 |
2013-08-15 |
Merck Patent Gmbh |
Furo [3, 2 - b] - and thieno [3, 2 - b] pyridine derivatives as tbk1 and ikk inhibitors
|
US9339503B2
(en)
|
2012-02-09 |
2016-05-17 |
Merck Patent Gmbh |
Tetrahydro-quinazolinone derivatives as TANK and PARP inhibitors
|
JP6097770B2
(ja)
|
2012-02-21 |
2017-03-15 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung |
フロピリジン誘導体
|
WO2013124026A1
(en)
|
2012-02-21 |
2013-08-29 |
Merck Patent Gmbh |
8 - substituted 2 -amino - [1,2,4] triazolo [1, 5 -a] pyrazines as syk tryrosine kinase inhibitors and gcn2 serin kinase inhibitors
|
WO2013126132A1
(en)
|
2012-02-21 |
2013-08-29 |
Merck Patent Gmbh |
Cyclic diaminopyrimidine derivatives
|
US20150051202A1
(en)
|
2012-03-07 |
2015-02-19 |
Merck Patent Gmbh |
Triazolopyrazine derivatives
|
CN104169284B
(zh)
|
2012-03-28 |
2017-03-29 |
默克专利股份公司 |
双环吡嗪酮衍生物
|
WO2013144532A1
(en)
|
2012-03-30 |
2013-10-03 |
Astrazeneca Ab |
3 -cyano- 5 -arylamino-7 -cycloalkylaminopyrrolo [1, 5 -a] pyrimidine derivatives and their use as antitumor agents
|
JP6007310B2
(ja)
|
2012-04-05 |
2016-10-12 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
ヒトtweak及びヒトil17に対する二重特異性抗体並びにその使用
|
EP3453713B1
(en)
|
2012-04-29 |
2021-09-08 |
Neupharma, Inc. |
Bufadienolide compounds substituted in position 3 by an amine group for use in the treatment of cancer
|
AU2013257018B2
(en)
|
2012-05-04 |
2017-02-16 |
Merck Patent Gmbh |
Pyrrolotriazinone derivatives
|
GB201211021D0
(en)
|
2012-06-21 |
2012-08-01 |
Cancer Rec Tech Ltd |
Pharmaceutically active compounds
|
ES2673873T3
(es)
|
2012-07-24 |
2018-06-26 |
Merck Patent Gmbh |
Derivados de hidroxiestatina para el tratamiento de la artrosis
|
EP2882746B1
(en)
|
2012-08-07 |
2016-12-07 |
Merck Patent GmbH |
Pyridopyrimidine derivatives as protein kinase inhibitors
|
SG11201500732TA
(en)
|
2012-08-08 |
2015-02-27 |
Merck Patent Gmbh |
(aza-)isoquinolinone derivatives
|
CN104736533B
(zh)
|
2012-08-17 |
2016-12-07 |
癌症治疗合作研究中心有限公司 |
Vegfr3抑制剂
|
CN102898330B
(zh)
*
|
2012-09-03 |
2015-02-25 |
浙江大学 |
秋水仙碱衍生物
|
WO2014041349A1
(en)
|
2012-09-12 |
2014-03-20 |
Cancer Therapeutics Crc Pty Ltd |
Tetrahydropyran-4-ylethylamino- or tetrahydropyranyl-4-ethyloxy-pyrimidines or -pyridazines as isoprenylcysteincarboxymethyl transferase inhibitors
|
WO2014047648A1
(en)
|
2012-09-24 |
2014-03-27 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
KR102200628B1
(ko)
|
2012-09-26 |
2021-01-08 |
메르크 파텐트 게엠베하 |
Parp 억제제로서의 퀴나졸리논 유도체
|
EP2911692B1
(en)
|
2012-10-26 |
2019-08-21 |
The University of Queensland |
Use of endocytosis inhibitors and antibodies for cancer therapy
|
CN104903467B
(zh)
|
2012-11-05 |
2020-09-08 |
Gmdx私人有限公司 |
确定体细胞突变原因的方法
|
US9725421B2
(en)
|
2012-11-12 |
2017-08-08 |
Neupharma, Inc. |
Substituted quinoxalines as B-raf kinase inhibitors
|
CA2891484A1
(en)
|
2012-11-16 |
2014-05-22 |
Merck Patent Gmbh |
3-aminocyclopentane carboxamide derivatives
|
US9353150B2
(en)
|
2012-12-04 |
2016-05-31 |
Massachusetts Institute Of Technology |
Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
|
EP3381917B1
(en)
|
2013-01-31 |
2021-09-08 |
Bellus Health Cough Inc. |
Imidazopyridine compounds and uses thereof
|
JP6321685B2
(ja)
|
2013-02-25 |
2018-05-09 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung |
2−アミノ−3,4−ジヒドロ−キナゾリン誘導体、およびそのカテプシンd阻害剤としての使用
|
CN105026397B
(zh)
|
2013-03-05 |
2017-06-30 |
默克专利股份公司 |
作为抗癌剂的9‑(芳基或杂芳基)‑2‑(吡唑基、吡咯烷基或环戊基)氨基嘌呤衍生物
|
EP2972394A4
(en)
|
2013-03-15 |
2016-11-02 |
Sloan Kettering Inst Cancer |
HSP90 TARGETING CARDIAC IMAGING AND TREATMENT THEREOF
|
AR095443A1
(es)
|
2013-03-15 |
2015-10-14 |
Fundación Centro Nac De Investig Oncológicas Carlos Iii |
Heterociclos condensados con acción sobre atr
|
US9937137B2
(en)
|
2013-03-15 |
2018-04-10 |
Neurocentria, Inc. |
Magnesium compositions and uses thereof for cancers
|
WO2014161570A1
(en)
|
2013-04-03 |
2014-10-09 |
Roche Glycart Ag |
Antibodies against human il17 and uses thereof
|
US20160115146A1
(en)
|
2013-06-07 |
2016-04-28 |
Universite Catholique De Louvain |
3-carboxy substituted coumarin derivatives with a potential utility for the treatment of cancer diseases
|
WO2014205511A1
(en)
|
2013-06-25 |
2014-12-31 |
University Of Canberra |
Methods and compositions for modulating cancer stem cells
|
RU2718876C2
(ru)
|
2013-08-23 |
2020-04-15 |
Ньюфарма, Инк. |
Некоторые химические соединения, композиции и способы
|
EP3046560B1
(en)
|
2013-09-18 |
2021-01-06 |
EpiAxis Therapeutics Pty Ltd |
Stem cell modulation ii
|
US20160298197A1
(en)
|
2013-10-01 |
2016-10-13 |
Queensland University Of Technology |
Kits and methods for diagnosis, screening, treatment and disease monitoring
|
US8980273B1
(en)
|
2014-07-15 |
2015-03-17 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
US8986691B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
GB201403536D0
(en)
|
2014-02-28 |
2014-04-16 |
Cancer Rec Tech Ltd |
Inhibitor compounds
|
WO2016029262A1
(en)
|
2014-08-25 |
2016-03-03 |
University Of Canberra |
Compositions for modulating cancer stem cells and uses therefor
|
ES2883628T3
(es)
|
2014-11-17 |
2021-12-09 |
Univ Queensland |
Biomarcadores de glucoproteínas para adenocarcinoma de esófago y esófago de Barrett y usos de los mismos
|
MA41179A
(fr)
|
2014-12-19 |
2017-10-24 |
Cancer Research Tech Ltd |
Composés inhibiteurs de parg
|
GB201501870D0
(en)
|
2015-02-04 |
2015-03-18 |
Cancer Rec Tech Ltd |
Autotaxin inhibitors
|
GB201502020D0
(en)
|
2015-02-06 |
2015-03-25 |
Cancer Rec Tech Ltd |
Autotaxin inhibitory compounds
|
CA2976227C
(en)
|
2015-02-17 |
2023-10-24 |
Neupharma, Inc. |
Quinazoline derivatives and their use in treatment of cancer
|
GB201510019D0
(en)
|
2015-06-09 |
2015-07-22 |
Cancer Therapeutics Crc Pty Ltd |
Compounds
|
CN113336746A
(zh)
|
2015-08-04 |
2021-09-03 |
常州千红生化制药股份有限公司 |
N-(吡啶-2-基)-4-(噻唑-5-基)嘧啶-2-胺类化合物作为治疗性化合物
|
JP6850294B2
(ja)
|
2015-08-26 |
2021-03-31 |
ジーエムディーエックス カンパニー プロプライエタリー リミテッド |
癌の再発を検出する方法
|
JP7412079B2
(ja)
|
2015-12-23 |
2024-01-12 |
レプルカ プロプライアタリー リミティド |
核酸オリゴマーとその用途
|
CN108883155A
(zh)
|
2016-02-01 |
2018-11-23 |
堪培拉大学 |
蛋白化合物及其用途
|
EP3417294B8
(en)
|
2016-02-15 |
2022-05-04 |
Astrazeneca AB |
Methods comprising fixed intermittent dosing of cediranib
|
US10844067B2
(en)
|
2016-04-15 |
2020-11-24 |
Cancer Research Technology Limited |
Heterocyclic compounds as RET kinase inhibitors
|
GB2554333A
(en)
|
2016-04-26 |
2018-04-04 |
Big Dna Ltd |
Combination therapy
|
WO2017197045A1
(en)
|
2016-05-11 |
2017-11-16 |
Movassaghi Mohammad |
Convergent and enantioselective total synthesis of communesin analogs
|
DK3490565T3
(da)
|
2016-07-29 |
2022-07-11 |
Rapt Therapeutics Inc |
Azetidinderivater som chemokinreceptormodulatorer og anvendelser deraf
|
EP4006035B1
(en)
|
2016-08-15 |
2023-11-22 |
Neupharma, Inc. |
Quinazoline derivatives as tyrosine kinase inhibitors for the treatment of cancer
|
US10919896B2
(en)
|
2016-09-22 |
2021-02-16 |
Cancer Research Technology Limited |
Preparation and uses of pyrimidinone derivatives
|
GB201617103D0
(en)
|
2016-10-07 |
2016-11-23 |
Cancer Research Technology Limited |
Compound
|
US10786502B2
(en)
|
2016-12-05 |
2020-09-29 |
Apros Therapeutics, Inc. |
Substituted pyrimidines containing acidic groups as TLR7 modulators
|
KR102495436B1
(ko)
|
2016-12-05 |
2023-02-02 |
에이프로스 테라퓨틱스, 인크. |
산성 기를 함유하는 피리미딘 화합물
|
SG11201907095UA
(en)
|
2017-02-01 |
2019-08-27 |
Aucentra Therapeutics Pty Ltd |
DERIVATIVES OF N-CYCLOALKYL/HETEROCYCLOALKYL-4-(IMIDAZO [1,2-a]PYRIDINE)PYRIMIDIN-2-AMINE AS THERAPEUTIC AGENTS
|
EP3592730B1
(en)
|
2017-03-09 |
2021-08-04 |
Truly Translational Sweden AB |
Prodrugs of sulfasalazine, pharmaceutical compositions thereof and their use in the treatment of autoimmune disease
|
GB201704325D0
(en)
|
2017-03-17 |
2017-05-03 |
Argonaut Therapeutics Ltd |
Compounds
|
GB201705971D0
(en)
|
2017-04-13 |
2017-05-31 |
Cancer Res Tech Ltd |
Inhibitor compounds
|
WO2018209239A1
(en)
|
2017-05-11 |
2018-11-15 |
Massachusetts Institute Of Technology |
Potent agelastatin derivatives as modulators for cancer invasion and metastasis
|
CN108864079B
(zh)
|
2017-05-15 |
2021-04-09 |
深圳福沃药业有限公司 |
一种三嗪化合物及其药学上可接受的盐
|
US11161839B2
(en)
|
2017-05-26 |
2021-11-02 |
The Institute Of Cancer Research: Royal Cancer Hospital |
2-quinolone derived inhibitors of BCL6
|
IL270869B2
(en)
|
2017-05-26 |
2023-09-01 |
Cancer Research Tech Ltd |
Benzimidazolone derivative inhibitors of bcl6
|
US11883405B2
(en)
|
2017-05-31 |
2024-01-30 |
Amplio Pharma Ab |
Pharmaceutical composition comprising a combination of methotrexate and novobiocin, and the use of said composition in therapy
|
EP3648797A1
(en)
|
2017-07-05 |
2020-05-13 |
EPOS-Iasis Research and Development, Ltd |
Multifunctional conjugates
|
ES2940407T3
(es)
|
2017-08-01 |
2023-05-08 |
Merck Patent Gmbh |
Derivados de tiazolopiridina como antagonistas de los receptores de adenosina
|
EP3668882A1
(en)
|
2017-08-18 |
2020-06-24 |
Cancer Research Technology Limited |
Pyrrolo[2,3-b]pyridine compounds and their use in the treatment of cancer
|
DK3672951T3
(da)
|
2017-08-21 |
2023-11-20 |
Merck Patent Gmbh |
Quinoxalinderivater som adenosinreceptorantagonister
|
JP7287952B2
(ja)
|
2017-08-21 |
2023-06-06 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
アデノシン受容体アンタゴニストとしてのベンズイミダゾール誘導体
|
TWI702205B
(zh)
|
2017-10-06 |
2020-08-21 |
俄羅斯聯邦商拜奧卡德聯合股份公司 |
表皮生長因子受體抑制劑
|
US10640508B2
(en)
|
2017-10-13 |
2020-05-05 |
Massachusetts Institute Of Technology |
Diazene directed modular synthesis of compounds with quaternary carbon centers
|
NL2019801B1
(en)
|
2017-10-25 |
2019-05-02 |
Univ Leiden |
Delivery vectors
|
BR112020009055A2
(pt)
|
2017-11-06 |
2020-11-03 |
Rapt Therapeutics, Inc. |
moduladores de receptor de quimiocina para tratamento de câncer positivo para vírus epstein barr
|
EP3489222A1
(en)
|
2017-11-23 |
2019-05-29 |
medac Gesellschaft für klinische Spezialpräparate mbH |
Sulfasalazine salts, production processes and uses
|
ES2965337T3
(es)
|
2017-11-23 |
2024-04-12 |
Medac Ges Fuer Klinische Spezialpraeparate Mbh |
Composición farmacéutica para administración oral que contiene sulfasalazina y/o una sal orgánica de sulfasalazina, proceso de producción y uso
|
EP3740484B1
(en)
|
2018-01-15 |
2024-09-11 |
Aucentra Therapeutics Pty Ltd |
5-(pyrimidin-4-yl)thiazol-2-yl urea derivatives as therapeutic agents
|
GB201801128D0
(en)
|
2018-01-24 |
2018-03-07 |
Univ Oxford Innovation Ltd |
Compounds
|
IL276295B2
(en)
|
2018-01-26 |
2024-02-01 |
Rapt Therapeutics Inc |
Modulators of chemokine receptors and their uses
|
WO2019157225A2
(en)
|
2018-02-08 |
2019-08-15 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
WO2019175093A1
(en)
|
2018-03-12 |
2019-09-19 |
Astrazeneca Ab |
Method for treating lung cancer
|
MX2020010805A
(es)
|
2018-04-13 |
2021-01-29 |
Cancer Research Tech Ltd |
Inhibidores de bcl6.
|
CN112423747A
(zh)
|
2018-04-27 |
2021-02-26 |
云杉生物科学公司 |
用于治疗睾丸肾上腺残余瘤和卵巢肾上腺残余瘤的方法
|
GB201809102D0
(en)
|
2018-06-04 |
2018-07-18 |
Univ Oxford Innovation Ltd |
Compounds
|
JP7351859B2
(ja)
|
2018-06-04 |
2023-09-27 |
アプロス セラピューティクス, インコーポレイテッド |
Tlr7の調節に関係する疾患を処置するのに有用な酸性基を含むピリミジン化合物
|
EP3802544A1
(en)
|
2018-06-05 |
2021-04-14 |
RAPT Therapeutics, Inc. |
Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses
|
GB201810092D0
(en)
|
2018-06-20 |
2018-08-08 |
Ctxt Pty Ltd |
Compounds
|
GB201810581D0
(en)
|
2018-06-28 |
2018-08-15 |
Ctxt Pty Ltd |
Compounds
|
WO2020068600A1
(en)
|
2018-09-24 |
2020-04-02 |
Rapt Therapeutics, Inc. |
Ubiquitin-specific-processing protease 7 (usp7) modulators and uses thereof
|
US20210361669A1
(en)
|
2018-10-25 |
2021-11-25 |
Merck Patent Gmbh |
5-azaindazole derivatives as adenosine receptor antagonists
|
BR112021007435A2
(pt)
|
2018-10-25 |
2021-08-03 |
Merck Patent Gmbh |
derivados de 5-azaindazol como antagonistas de receptor de adenosina
|
GB201819126D0
(en)
|
2018-11-23 |
2019-01-09 |
Cancer Research Tech Ltd |
Inhibitor compounds
|
AR117844A1
(es)
|
2019-01-22 |
2021-09-01 |
Merck Patent Gmbh |
Derivados de tiazolopiridina como antagonistas del receptor de adenosina
|
JP2022524759A
(ja)
|
2019-03-07 |
2022-05-10 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Shp2アンタゴニストとしてのカルボキサミド-ピリミジン誘導体
|
CN111747950B
(zh)
|
2019-03-29 |
2024-01-23 |
深圳福沃药业有限公司 |
用于治疗癌症的嘧啶衍生物
|
US20230085408A1
(en)
|
2019-04-05 |
2023-03-16 |
STORM Therapeutics Ltd. |
Mettl3 inhibitory compounds
|
CA3127475A1
(en)
|
2019-04-08 |
2020-10-15 |
Merck Patent Gmbh |
Pyrimidinone derivatives as shp2 antagonists
|
GB201905328D0
(en)
|
2019-04-15 |
2019-05-29 |
Azeria Therapeutics Ltd |
Inhibitor compounds
|
WO2020247054A1
(en)
|
2019-06-05 |
2020-12-10 |
Massachusetts Institute Of Technology |
Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
|
GB201908885D0
(en)
|
2019-06-20 |
2019-08-07 |
Storm Therapeutics Ltd |
Therapeutic compounds
|
US20220298143A1
(en)
|
2019-08-31 |
2022-09-22 |
Etern Biopharma (Shanghai) Co., Ltd. |
Pyrazole Derivatives for FGFR Inhibitor and Preparation Method Thereof
|
TW202120501A
(zh)
|
2019-09-20 |
2021-06-01 |
美商愛德亞生物科學公司 |
作為parg抑制劑之4-取代的吲哚及吲唑磺醯胺衍生物
|
GB201913988D0
(en)
|
2019-09-27 |
2019-11-13 |
Celleron Therapeutics Ltd |
Novel treatment
|
GB201914860D0
(en)
|
2019-10-14 |
2019-11-27 |
Cancer Research Tech Ltd |
Inhibitor compounds
|
GB201915831D0
(en)
|
2019-10-31 |
2019-12-18 |
Cancer Research Tech Ltd |
Compounds, compositions and therapeutic uses thereof
|
GB201915828D0
(en)
|
2019-10-31 |
2019-12-18 |
Cancer Research Tech Ltd |
Compounds, compositions and therapeutic uses thereof
|
GB201915829D0
(en)
|
2019-10-31 |
2019-12-18 |
Cancer Research Tech Ltd |
Compounds, compositions and therapeutic uses thereof
|
KR20220113431A
(ko)
|
2019-12-02 |
2022-08-12 |
스톰 테라퓨틱스 리미티드 |
Mettl3 저해제로서의 폴리헤테로환식 화합물
|
GB202004960D0
(en)
|
2020-04-03 |
2020-05-20 |
Kinsenus Ltd |
Inhibitor compounds
|
GB202008201D0
(en)
|
2020-06-01 |
2020-07-15 |
Neophore Ltd |
Inhibitor compounds
|
GB202012482D0
(en)
|
2020-08-11 |
2020-09-23 |
Univ Of Huddersfield |
Novel compounds and therapeutic uses thereof
|
GB202012969D0
(en)
|
2020-08-19 |
2020-09-30 |
Univ Of Oxford |
Inhibitor compounds
|
WO2022074379A1
(en)
|
2020-10-06 |
2022-04-14 |
Storm Therapeutics Limited |
Mettl3 inhibitory compounds
|
US20240101589A1
(en)
|
2020-10-08 |
2024-03-28 |
Strom Therapeutics Limited |
Inhibitors of mettl3
|
US12030888B2
(en)
|
2021-02-24 |
2024-07-09 |
Massachusetts Institute Of Technology |
Himastatin derivatives, and processes of preparation thereof, and uses thereof
|
GB202102895D0
(en)
|
2021-03-01 |
2021-04-14 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
WO2022197641A1
(en)
|
2021-03-15 |
2022-09-22 |
Rapt Therapeutics, Inc. |
1h-pyrazolo[3,4-d]pyrimidin-6-yl-amine derivatives as hematopoietic progenitor kinase 1 (hpk1) modulators and/or inhibitors for the treatment of cancer and other diseases
|
IL308163A
(en)
|
2021-05-03 |
2024-01-01 |
Merck Patent Gmbh |
FC antigen-binding conjugate drug fragments targeting HER2
|
AU2022276958A1
(en)
|
2021-05-17 |
2023-12-07 |
Hk Inno.N Corporation |
Benzamide derivative, method for preparing same, and pharmaceutical composition for prevention or treatment of cancer containing same as active ingredient
|
IL308818A
(en)
|
2021-05-25 |
2024-01-01 |
Merck Patent Gmbh |
FC antigen-binding conjugate drug fragments targeting EGFR
|
GB202107907D0
(en)
|
2021-06-02 |
2021-07-14 |
Storm Therapeutics Ltd |
Combination therapies
|
GB202108383D0
(en)
|
2021-06-11 |
2021-07-28 |
Argonaut Therapeutics Ltd |
Compounds useful in the treatment or prevention of a prmt5-mediated disorder
|
GB202110373D0
(en)
|
2021-07-19 |
2021-09-01 |
Neophore Ltd |
Inhibitor compounds
|
IT202100023357A1
(it)
|
2021-09-09 |
2023-03-09 |
Cheirontech S R L |
Peptidi con attività anti-angiogenica
|
EP4413000A1
(en)
|
2021-10-04 |
2024-08-14 |
FoRx Therapeutics AG |
N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer
|
WO2023057389A1
(en)
|
2021-10-04 |
2023-04-13 |
Forx Therapeutics Ag |
Parg inhibitory compounds
|
GB202117224D0
(en)
|
2021-11-29 |
2022-01-12 |
Neophore Ltd |
Inhibitor compounds
|
GB202117225D0
(en)
|
2021-11-29 |
2022-01-12 |
Neophore Ltd |
Protac compounds
|
AU2023205435A1
(en)
|
2022-01-10 |
2024-08-22 |
Cancer Research Horizons |
Substituted heterocycles as hset inhibitors
|
GB202202006D0
(en)
|
2022-02-15 |
2022-03-30 |
Chancellor Masters And Scholars Of The Univ Of Oxford |
Anti-cancer treatment
|
GB202202199D0
(en)
|
2022-02-18 |
2022-04-06 |
Cancer Research Tech Ltd |
Compounds
|
WO2023175184A1
(en)
|
2022-03-17 |
2023-09-21 |
Forx Therapeutics Ag |
2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer
|
WO2023175185A1
(en)
|
2022-03-17 |
2023-09-21 |
Forx Therapeutics Ag |
2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer
|
GB202204935D0
(en)
|
2022-04-04 |
2022-05-18 |
Cambridge Entpr Ltd |
Nanoparticles
|
US20230322741A1
(en)
|
2022-04-06 |
2023-10-12 |
Rapt Therapeutics, Inc. |
Chemokine receptor modulators and uses thereof
|
WO2023218201A1
(en)
|
2022-05-11 |
2023-11-16 |
Cancer Research Technology Limited |
Ikk inhibitors
|
GB202209404D0
(en)
|
2022-06-27 |
2022-08-10 |
Univ Of Sussex |
Compounds
|
WO2024030825A1
(en)
|
2022-08-01 |
2024-02-08 |
Neupharma, Inc |
Crystalline salts of crystalline salts of (3s,5r,8r,9s,10s,13r,14s,17r)-14-hydroxy-10,13-dimethyl-17-(2- oxo-2h-pyran-5-yl)hexadecahydro-1h-cyclopenta[a]phenanthren-3-yl piperazine-1-carboxylate
|
GB202213167D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
GB202213166D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
GB202213162D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Prodrugs
|
GB202213163D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
GB202213164D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
WO2024074497A1
(en)
|
2022-10-03 |
2024-04-11 |
Forx Therapeutics Ag |
Parg inhibitory compound
|
WO2024094962A1
(en)
|
2022-11-02 |
2024-05-10 |
Cancer Research Technology Limited |
Pyrido[2,3-d]pyrimidin-2-amine derivatives as egfr inhibitors for the treatment of cancer
|
WO2024094963A1
(en)
|
2022-11-02 |
2024-05-10 |
Cancer Research Technology Limited |
2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one and 7-amino-1-pyrimido[4,5-d]pyrimidin-2(1 h)-one derivatives as egfr inhibitors for the treatment of cancer
|
WO2024099898A1
(en)
|
2022-11-07 |
2024-05-16 |
Merck Patent Gmbh |
Substituted bi-and tricyclic hset inhibitors
|
GB202218672D0
(en)
|
2022-12-12 |
2023-01-25 |
Storm Therapeutics Ltd |
Inhibitory compounds
|
GB202300881D0
(en)
|
2023-01-20 |
2023-03-08 |
Neophore Ltd |
Inhibitor compounds
|
WO2024173453A1
(en)
|
2023-02-14 |
2024-08-22 |
Ideaya Biosciences, Inc. |
Heteroaryl-substituted imidazopyridine compounds
|
WO2024173524A1
(en)
|
2023-02-14 |
2024-08-22 |
Ideaya Biosciences, Inc. |
Heteroaryl-substituted benzimidazole compounds
|
WO2024173514A1
(en)
|
2023-02-14 |
2024-08-22 |
Ideaya Biosciences, Inc. |
Amide and ester-substituted imidazopyridine compounds
|
WO2024173530A1
(en)
|
2023-02-14 |
2024-08-22 |
Ideaya Biosciences, Inc. |
Heteroaryl-substituted pyrazolo/imidazo pyridine compounds
|
US20240327430A1
(en)
|
2023-03-10 |
2024-10-03 |
Breakpoint Therapeutics Gmbh |
Novel compounds, compositions, and therapeutic uses thereof
|
WO2024209035A1
(en)
|
2023-04-05 |
2024-10-10 |
Forx Therapeutics Ag |
Parg inhibitory compounds
|